Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURAN study of buparlisib plus paclitaxel versus paclitaxel alone in recurrent or metastatic head and neck squamous cell carcinoma
2024-517251-12-00Phase 3Completed
- Sponsor
- Adlai Nortye
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Buparlisib + paclitaxel with Paclitaxel alone (2 arms). Primary endpoint: Overall survival. Started Sep 2024; status: completed.
02
Drugs
buparlisibpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-517251-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517251-12-00.